Trial *
Publication Manomaipiboon A, Research square (2022) (preprint)
Dates: 2021-09-01 to 2021-11-30
Funding: Public/non profit (Navamindradhiraj University)
Conflict of interest: No

Methods
RCT
Blinding: double blinding
Location : Single center / Thailand
Follow-up duration (days): 28
Inclusion criteria
  • Men and women aged 18–80 years
  • non-pregnant or breast-feeding women
  • COVID-19 confirmed using a positive RT-PCR
  • within 72 hours of a positive result or onset of symptoms
  • mild-to-moderate symptoms as defined by the World Health Organization (WHO) severity score for COVID-19
Exclusion criteria
  • Allergic to ivermectin
  • potential for a drug-drug interaction with ivermectin, such as tamoxifen or warfarin
  • previously treated with ivermectin in the last 7 days
  • received any herbal medicine
  • severe chronic illness (severe congestive heart failure, chronic kidney disease stage 4–5, chronic liver disease, terminal cancer)
  • concurrent bacterial infection
  • unwilling to participate in the trial
  • severe symptoms, likely due to cytokine release syndrome
  • uncontrolled co-morbidities
  • immunocompromised status
Interventions
Treatment
Ivermectin
12 mg/day orally for 5 days
Control
Placebo

Participants
Randomized
participants :
Ivermectin=37
Placebo=37
Characteristics of participants
N= 74
Mean age : NR
27 males
Severity : Mild: n=* / Moderate: n=* / Severe: n=0 Critical: n=0
Number of vaccinated participants: 23
Primary outcome
In the register
NR
In the report
Viral clearance of SARS-CoV-2 on day 7 and 14 after intervention
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Yes
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
Some concerns
General comment Only the pre-print article was used in data extraction and assessment of risk of bias. No registry was available and the protocol referred to as a supplementary file in the article was not available. Therefore, it is not clear whether population, intervention and outcomes were prespecified or whether there was a target sample size.